reports
Oncocyte Reports First Quarter 2024 Financial Results
Oncocyte Reports First Quarter 2024 Financial Results Conference Call on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc.On track to ship research use only (RUO) GraftAssure™ transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024. IVD kits are under development for FDA submission....
Oncocyte to Announce First Quarter 2024 Financial Results
Oncocyte to Announce First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. Interested parties may access the l...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,250 shares of its common stock to eleven newly-hired employees, with a grant date of May 6, 2024 (the "Grant Date"). The restricted stock units were granted pursua...
TELA Bio Reports First Quarter 2024 Financial Results
TELA Bio Reports First Quarter 2024 Financial Results MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Reported revenue of $16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023;Delivered the 13th consecutive quarter of at least 35% year-over-year growth;Increased demand for OviTex® and OviTex PRS Reinforced Tis...
- Jonathan Chaplin
SATS: model update
This note covers updates to the model following consolidated EchoStar results. We increased service revenue and EBITDA. Our free cash flow is up very modestly. The company has five to seven months to raise capital. We updated our valuation to $95 / share. We will have another update out once we get the Dish, DBS & Hughes 10-Qs.
- Jonathan Chaplin
EchoStar: Quick thoughts following the call
In this brief note, we cover: 1) securitizable spectrum value; 2) when cash runs out; 3) the implications of the DBS lawsuit for raising new capital; 4) operating improvements in prepaid wireless; 4) progress on cost savings; 5) preliminary thoughts on a new strategy in postpaid wireless.
- Jonathan Chaplin
SATS 1Q24 Quick Take: Operating trends fine; focus will be on capital ...
Operating results were generally a bit better than expected. The Company appears to be doing what it can to preserve cash. The cash burn was $100MM higher than we expected and $200MM higher than consensus expected. We estimate that the Company has enough cash to get through the next two quarters, but barely.
- Laura Chico
- Jonathan Moreland
RHP RYMAN HOSPITALITY PROPERTIES INC.
HUBB HUBBELL INCORPORATED CLASS B
ECL ECOLAB INC.
CTRN CITI TRENDS INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
EFR ENERGY FUELS
HTLD HEARTLAND EXPRESS INC.
CRVS CORVUS PHARMACEUTICALS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
EAF GRAFTECH INTERNATIONAL
FRAF FRANKLIN FINANCIAL SERVICES CO.
HQL TEKLA LIFE SCIENCES INVESTORS
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
TDUP THREDUP INC.
TBBK THE BANCORP
VPV INC.
MEGI INVESCO PA VALUE MUNI INC TST
NPCT MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
ASGI NUVEEN CORE PLUS IMPACT FD
DBD ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
DIEBOLD NIXDORF INCORPORATED
- Blair Levin
NSR Policy: ACP’s Perils of Pauline
In this Weekend Update, we review the multiple activities affecting the prospects for an ACP extension, including one legislative solution that was pulled from a mark-up, a Senate hearing on the subject, and an effort to attach an extension to FAA reauthorization. Our bottom line remains: 1. With the ACP funds about to run out, recipients in May or June are likely to start having to make hard choices about what they are willing to pay for. 2. We agree with the consensus in government and indus...
- Wedbush Research
LOGN LOGITECH INTERNATIONAL S.A.
VMW VMWARE INC. CLASS A
QRVO QORVO INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SGMO SANGAMO THERAPEUTICS INC.
SBUX STARBUCKS CORPORATION
RWT REDWOOD TRUST INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
PCRX PACIRA BIOSCIENCES INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MCD MCDONALD'S CORPORATION
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FTNT FORTINET INC.
FATE FATE THERAPEUTICS INC
EXLS EXLSERVICE HOLDINGS INC.
EAT BRINKER INTERNATIONAL INC.
DENN DENNY'S CORPORATION
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
SWKS SKYWORKS SOLUTIONS INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
TMHC TAYLOR MORRISON HOME CORPORATION
HPE HEWLETT PACKARD ENTERPRISE CO.
TWTR TWITTER INC.
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
HEAR TURTLE BEACH CORP.
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
AX AXOS FINANCIAL INC.
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
PINS PINTEREST INC. CLASS A
BCEL ATRECA
DELL DELL TECHNOLOGIES INC CLASS C
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
LC LENDINGCLUB CORP
SMCI SUPER MICRO COMPUTER
AQST INC.
IDYA AQUESTIVE THERAPEUTICS
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
CRSR ADICET BIO INC
ITOS CORSAIR GAMING
ZNTL ITEOS THERAPEUTICS
PRAX ZENTALIS PHARMACEUTICALS
FUBO PRAXIS PRECISION MEDICINES
TVTX FUBOTV
LSEA TRAVERE THERAPEUTICS INC
VRDN LANDSEA HOMES CORP (A)
DAWN VIRIDIAN THERAPEUTICS INC
ELEV DAY ONE BIOPHARMACEUTICALS INC
OMGA ELEVATION ONCOLOGY
LBPH OMEGA THERAPEUTICS
THRX LONGBOARD PHARMACEUTICALS
MRVL THESEUS PHARMACEUTICALS
STX INC.
DSGN MARVELL TECHNOLOGY INC
ATXS SEAGATE TECHNOLOGY HLDGS PLC
AVTE DESIGN THERAPEUTICS INC
GFS ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX GLOBALFOUNDRIES INC
FUSN RALLYBIO CORP
VIGL KARUNA THERAPEUTICS INC
EWTX FUSION PHARMACEUTICALS INC
VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Liana Moussatos
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
BCEL ATRECA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
THRX THESEUS PHARMACEUTICALS
DSGN INC.
ATXS DESIGN THERAPEUTICS INC
AVTE ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX RALLYBIO CORP
FUSN KARUNA THERAPEUTICS INC
VIGL FUSION PHARMACEUTICALS INC
EWTX VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
- Blair Levin
NSR Policy: The Interconnections of ACP, Spectrum, Title II, and the S...
In this weekend update, we reconsider our initial takes on several events last week and how they could be affected by events this week. Specifically, we look at the interplay of the FCC’s Title II Order, the Second Circuit opinion upholding New York State’s mandate for ISPs to offer low-income households a low-cost broadband offering, Senator Cantwell’s draft spectrum bill, and how all are affected by the end of ACP funding in the next few weeks.
Ultralife Corporation Reports First Quarter Results
Ultralife Corporation Reports First Quarter Results NEWARK, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the first quarter ended March 31, 2024 with the following highlights: Sales of $41.9 million representing a 31.4% year-over-year increase, including 54.7% growth in medical market salesGross profit of $11.5 million, or 27.4% of revenue, compared to $7.4 million, or 23.3% of revenue for the 2023 first quarterOperating income of $4.1 million versus breakeven for the 2023 first quarterGAAP EPS of $0.18 compared to a loss of ...
TELA Bio to Announce First Quarter 2024 Financial Results
TELA Bio to Announce First Quarter 2024 Financial Results MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2024 financial results on Thursday, May 9, 2024. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors...
Donegal Group Inc. Announces First Quarter 2024 Results
Donegal Group Inc. Announces First Quarter 2024 Results MARIETTA, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Donegal Group Inc. (NASDAQ: DGICA) and (NASDAQ: DGICB) today reported its financial results for the first quarter of 2024. Significant Items for First Quarter of 2024 (all comparisons to first quarter of 2023): Net premiums earned increased 5.8% to $227.7 millionNet premiums written1 increased 6.0% to $251.4 millionCombined ratio of 102.4%, compared to 101.2%Net income of $6.0 million, or $0.18 per diluted Class A share, compared to $5.2 million, or $0.16 per diluted Class A shareAn...
- Blair Levin
Donegal Group Inc. Announces Increase in Quarterly Dividend
Donegal Group Inc. Announces Increase in Quarterly Dividend MARIETTA, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Donegal Group Inc. (NASDAQ:DGICA) and (NASDAQ:DGICB) reported today that its board of directors declared a regular quarterly cash dividend of $0.1725 per share of the Company’s Class A common stock and $0.155 per share of the Company’s Class B common stock. The dividends are payable on May 22, 2024 to stockholders of record as of the close of business on May 8, 2024. These dividends represent percentage increases of 1.5% for the Company’s Class A common stock and 1.6% for the C...
Oncocyte Corporation: 2 directors
Two Directors at Oncocyte Corporation bought 37,288 shares at 2.950USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex...
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.) MALVERN, Pa., April 15, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix, specifically designed for use in laparoscopic and roboti...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.